Brief: Century Therapeutics Announces First Patient Dosed In First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 In Relapsed Or Refractory CD19 Positive B-Cell Lymphomas
08/02/2023 12:40
Feb 8 (Reuters) - Century Therapeutics Inc IPSC.O :
* CENTURY THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
FIRST-IN-HUMAN PHASE 1 ELIPSE-1 TRIAL EVALUATING CNTY-101 IN
RELAPSED OR REFRACTORY CD19 POSITIVE B-CELL LYMPHOMAS
Source text for Eikon: ID:nGNX2XZtPf
Further company coverage: IPSC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Century Therapeutics
See all newsCentury Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Century Therapeutics Q2 net loss misses estimates on lease termination loss
Brief: Century Therapeutics Q2 Net Income USD -34.55 Million Vs. IBES Estimate USD -22.4 Million
Century Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Century Therapeutics Inc expected to post a loss of 11 cents a share - Earnings Preview